Beyond Air, Inc. XAIR

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
34/100
Developing

About Beyond Air, Inc.

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral … Full XAIR analysis →

Competitive advantage assessment

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.99). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.98). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.09). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.14). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
7

Where XAIR ranks in Medical Devices

Beyond Air, Inc. ranks #120 of 160 scored companies in Medical Devices by moat score — the top 75%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near XAIR in Medical Devices
# Company Moat score Rating
116 Senseonics Holdings, Inc. SENS 36/100 Developing
117 Ainos, Inc. AIMD 35/100 Developing
118 AINOS INC C/WTS 29/07/2027 (TO AIMDW 35/100 Developing
119 Lucid Diagnostics Inc. LUCD 34/100 Developing
120 Beyond Air, Inc. XAIR 34/100 Developing
121 Tenon Medical, Inc. TNON 34/100 Developing
122 Bone Biologics Corp BBLG 34/100 Developing
123 BONE BIOLOGICS CORP C/WTS (TO P BBLGW 33/100 Developing
124 NeuroMetrix, Inc. NURO 33/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How XAIR scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 7 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 22 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 58 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 52 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 28 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 62 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding XAIR's moat

What is Beyond Air, Inc.'s moat score?

Beyond Air, Inc. (XAIR) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #120 of 160 scored companies in Medical Devices, the top 75%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Growth Durability (62/100) and its weakest is Pricing Power & Consumable Moat (7/100).

How does Beyond Air, Inc. compare with other Medical Devices companies?

Beyond Air, Inc. ranks #120 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Lucid Diagnostics Inc. (LUCD) at 34 just above it and Tenon Medical, Inc. (TNON) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Beyond Air, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Beyond Air, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and XAIR scores: Pricing Power & Consumable Moat (7), R&D Pipeline & Capital Returns (22), FCF Quality & Cash Conversion (58), Commercial Execution (52), Capital Structure & Resilience (28), Growth Durability (62). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000